Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Cell therapy is one of the most exciting and dynamic fields in modern medicine. Yet there are still challenges such as reducing manufacturing timeframes and maintaining consistent performance in light of patient variability. Thermo Fisher Scientific is releasing a first-of-its-kind platform technology that enables isolation and activation of T cells in one step with a key differentiator: an active release mechanism for clinical trial or commercial manufacturing. The Gibco™ CTS™ Detachable Dynabeads™ CD3/CD28 Kit possesses a proprietary active release mechanism that enables the intentional early release of Dynabeads from the cells before the naturally occurring release at day 4 or 5. Conjugated to highly specific, single-domain VHH antibodies that target specific clusters of differentiation markers, the performance exhibits consistent and optimal isolation, activation, and purity of target T cell populations while addressing the biological variability that cell therapy manufacturers are facing.
Attend this webinar to learn about: